Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;25(7):1686-95.
doi: 10.1007/s11095-008-9549-8. Epub 2008 Feb 22.

Prolonging the in vivo residence time of prostaglandin E(1) with biodegradable nanoparticles

Affiliations

Prolonging the in vivo residence time of prostaglandin E(1) with biodegradable nanoparticles

Tsutomu Ishihara et al. Pharm Res. 2008 Jul.

Abstract

Purpose: Prostaglandins have potent and diverse biologic activities, but their clinical application is severely restricted, mainly due to rapid inactivation in vivo. In order to modulate the pharmacokinetics of prostaglandin E(1) (PGE(1)), we prepared biodegradable nanoparticles as a drug carrier.

Methods: Nanoparticles encapsulating PGE(1) were prepared from a blend of poly(lactic acid) homopolymer and poly(ethylene glycol)-poly(lactide) block copolymer by the solvent diffusion method in the presence of iron.

Results: PGE(1) was efficiently and stably embedded in the nanoparticles through interaction with iron, despite being relatively hydrophilic and having unstable chemical properties. Depending on the isomers and molecular weight of poly(lactic acid) selected, PGE(1) was gradually released from the nanoparticles at various rates into diluted serum in vitro. Both stable retention of PGE(1) in the nanoparticles and coating of the nanoparticles with poly(ethylene glycol) led to an extremely extended blood residence time of PGE(1), as well as preferential accumulation in vascular lesions.

Conclusions: These results suggest that the present strategy is useful to advance the clinical application of PGE(1) as a therapeutic agent for vascular disorders.

PubMed Disclaimer

References

    1. Expert Opin Drug Saf. 2007 Jan;6(1):45-52 - PubMed
    1. J Cell Sci. 1974 Jan;14(1):215-23 - PubMed
    1. Ann Rheum Dis. 2005 Aug;64(8):1132-6 - PubMed
    1. J Am Coll Cardiol. 1994 Nov 1;24(5):1382-90 - PubMed
    1. Pharm Res. 2001 Oct;18(10):1411-9 - PubMed

MeSH terms

LinkOut - more resources